ESR1 and breast carcinoma: As a competitive antagonist of estradiol, tamoxifen can bind to estrogen receptors in competition with estradiol and form a stable complex, which inhibits the transcription activity of the estrogen receptor and blocks breast cancer cells in G1 phase to inhibit tumor proliferation.